[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632019":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":47,"centralContacts":51,"locations":57,"responsibleParty":72,"collaborators":55,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":55,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":55,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":55,"overallStatus":60,"whyStopped":55,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14,19,23,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Period 1","EXPERIMENTAL","Participants will receive a single oral dose of acetaminophen.",[13],"Drug: Acetaminophen",{"label":15,"type":10,"description":16,"interventionNames":17},"Period 2","Participants will receive SC dose of PF-08653944 and single oral dose of acetaminophen.",[18,13],"Drug: PF-08653944",{"label":20,"type":10,"description":21,"interventionNames":22},"Period 3","Participants will receive SC dose of PF-0865394.",[18],{"label":24,"type":10,"description":21,"interventionNames":25},"Period 4",[18],{"label":27,"type":10,"description":16,"interventionNames":28},"Period 5",[18,13],{"label":30,"type":10,"description":31,"interventionNames":32},"Period 6","Participants will receive single SC dose of PF-08653944 and single oral dose of acetaminophen.",[18,13],[34,41],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","PF-08653944","Subcutaneous Injection",[15,20,24,27,30],[40],"MET097",{"type":35,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Acetaminophen","Oral suspension",[9,15,27,30],[46],"paracetamol",[48],{"name":49,"affiliation":5,"role":50},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[52],{"name":49,"role":53,"phone":54,"phoneExt":55,"email":56},"CONTACT","1-800-718-1021",null,"ClinicalTrials.gov_Inquiries@pfizer.com",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":55},"Pfizer Clinical Research Unit - New Haven","RECRUITING","New Haven","Connecticut","06511","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-72.92816,41.30815,{"lat":70,"lon":69},{"type":73,"investigatorFullName":55,"investigatorTitle":55,"investigatorAffiliation":55,"oldNameTitle":55,"oldOrganization":55},"SPONSOR","100632019","phase-1-a-study-to-learn-about-the-effect-of-study-medicine-called-pf-08653944-on-how-quickly-the-stomach-empties-its-content-in-healthy-adults-with-overweight-or-obesity-100632019",false,"NCT07508241","A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity","A PHASE 1, OPEN-LABEL, MULTIPLE DOSE STUDY TO INVESTIGATE THE IMPACT OF PF 08653944 ON GASTRIC EMPTYING IN ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY","Inclusion Criteria:\n\n* Adults ≥18 years at screening, male or female, generally healthy as determined by medical history, physical examination, laboratory tests, and ECG.\n* Body mass index (BMI) 27-45 kg\u002Fm² and body weight \\>50 kg (110 lb).\n* Participants with overweight or obesity\n\nExclusion Criteria:\n\n* History or presence of clinically significant medical conditions, including but not limited to:\n\n  --Cardiovascular, hepatic, renal, pulmonary, endocrine, hematologic, neurologic, gastrointestinal (including pancreatitis or gallbladder disease), or significant psychiatric disorders.\n* Any form of diabetes, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg\u002FdL.\n* Prior exposure to a GLP-1 receptor agonist within 90 days before first dose, or prior participation in a study with PF-08653944.",true,"ALL","18 Years","99 Years",{"count":86,"type":87},20,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.\n\nParticipants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects.\n\nThe information from this study may help researchers plan future studies of this medicine.",[93,94,95,96],"Obesity","Overweight and\u002For Obesity","Overweight","Drug Interaction","2026-04-20",{"date":99,"type":100},"2026-04-23","ACTUAL",{"date":102,"type":100},"2026-03-31",{"date":104,"type":87},"2027-01-27",{"name":5,"class":6},1]